Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: In vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor

European Journal of Pharmaceutical Sciences

Volumn 45, Issue 3, 2012, Pages 320-329

  Sheihet, Larisa ^a   Garbuzenko, Olga B ^b   Bushman, Jared ^a   Gounder, Murugesan K ^c   Minko, Tamara ^b,c   Kohn, Joachim ^a  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Anti tumor efficacy; Chremophor; Drug delivery; Paclitaxel; Toxicity; Tyrosine derived nanospheres

Indexed keywords

CREMOPHOR; NANOSPHERE; PACLITAXEL; TYROSINE DERIVED NANOSPHERE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERANCE; FEMALE; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG CARRIERS; FEMALE; GLYCEROL; HUMANS; MAXIMUM TOLERATED DOSE; MICE; MICE, NUDE; NANOSPHERES; NEOPLASMS; PACLITAXEL; PHARMACEUTICAL VEHICLES; TYROSINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84855801433     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2011.11.017     Document Type: Article

References (74)

1. J.D. Adams, K.P. Flora, B.R. Goldspiel, J.W. Wilson, S.G. Arbuck, and R. Finley Taxol: a history of pharmaceutical development and current pharmaceutical concerns J. Natl. Cancer Inst. Monogr. 1993 141 147
2. F. Ahmed, R.I. Pakunlu, A. Brannan, F. Bates, T. Minko, and D.E. Discher Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug J. Controlled Release 116 2006 150 158 (Pubitemid 44868999)
3. A.M. Al-Ghananeem, A.H. Malkawi, Y.M. Muammer, J.M. Balko, E.P. Black, W. Mourad, and E. Romond Intratumoral delivery of Paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations AAPS PharmSciTech. 10 2009 410 417
4. C. Allen, D. Maysinger, and A. Eisenberg Nano-engineering block copolymer aggregates for drug delivery Colloids Surf. B: Biointerfaces 16 1999 3 27
5. H.A. Bardelmeijer, M. Ouwehand, M.M. Malingre, J.H. Schellens, J.H. Beijnen, and O. van Tellingen Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut Cancer Chemother. Pharmacol. 49 2002 119 125 (Pubitemid 34119009)
6. S.L. Bourke, and J. Kohn Polymers derived from the amino acid l-tyrosine: polycarbonates, polyarylates and copolymers with poly(ethylene glycol) Adv. Drug Deliv. Rev. 55 2003 447 466 (Pubitemid 36423299)
7. J.M. Chan, L. Zhang, K.P. Yuet, G. Liao, J.W. Rhee, R. Langer, and O.C. Farokhzad PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery Biomaterials 30 2009 1627 1634
8. P. Chandna, J.J. Khandare, E. Ber, L. Rodriguez-Rodriguez, and T. Minko Multifunctional tumor-targeted polymer-peptide-drug delivery system for treatment of primary and metastatic cancers Pharm. Res. 27 2010 2296 2306
9. Cheng, R., Feng, F., Meng, F., Deng, C., Feijen, J., Zhong, Z., 2011. Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery. J. Controlled Release, Epub ahead of print.
10. A. Ciucci, P. Gianferretti, R. Piva, T. Guyot, T.J. Snape, S.M. Roberts, and M.G. Santoro Induction of apoptosis in estrogen receptor-negative breast cancer cells by natural and synthetic cyclopentenones: role of the IkappaB kinase/nuclear factor-kappaB pathway Mol. Pharmacol. 70 2006 1812 1821
11. T.H. Corbett, F.A. Valeriote, L. Demchik, N. Lowichik, L. Polin, C. Panchapor, S. Pugh, K. White, J. Kushner, J. Rake, M. Wentland, T. Golakoti, C. Hetzel, J. Ogino, G. Patterson, and R. Moore Discovery of cryptophycin-1 and BCN-183577: examples of strategies and problems in the detection of antitumor activity in mice Invest. New Drugs 15 1997 207 218 (Pubitemid 27453875)
12. A.D. Costache, L. Sheihet, K. Zaveri, D.D. Knight, and J. Kohn Polymer-drug interactions in tyrosine-derived triblock copolymer nanospheres: a computational modeling approach Mol. Pharm. 6 5 2009 1620 1627
13. B. Damascelli, G.L. Patelli, R. Lanocita, G. Di Tolla, L.F. Frigerio, A. Marchiano, F. Garbagnati, C. Spreafico, V. Ticha, C.R. Gladin, M. Palazzi, F. Crippa, C. Oldini, S. Calo, A. Bonaccorsi, F. Mattavelli, L. Costa, L. Mariani, and G. Cantu A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings AJR Am. J. Roentgenol. 181 2003 253 260 (Pubitemid 36741497)
14. F. Danhier, N. Lecouturier, B. Vroman, C. Jerome, J. Marchand-Brynaert, O. Feron, and V. Preat Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation J. Controlled Release 133 2009 11 17
15. J.A. Daniels, M.K. Gibson, L. Xu, S. Sun, M.I. Canto, E. Heath, J. Wang, M. Brock, and E. Montgomery Gastrointestinal tract epithelial changes associated with taxanes: marker of drug toxicity versus effect Am. J. Surg. Pathol. 32 2008 473 477 (Pubitemid 351398941)
16. N. Desai, V. Trieu, Z. Yao, L. Louie, S. Ci, A. Yang, C. Tao, T. De, B. Beals, D. Dykes, P. Noker, R. Yao, E. Labao, M. Hawkins, and P. Soon-Shiong Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel Clin. Cancer Res. 12 2006 1317 1324 (Pubitemid 43342524)
17. S.S. Dharap, Y. Wang, P. Chandna, J.J. Khandare, B. Qiu, S. Gunaseelan, P.J. Sinko, S. Stein, A. Farmanfarmaian, and T. Minko Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide Proc. Natl. Acad. Sci. USA 102 2005 12962 12967 (Pubitemid 41279472)
18. F. Dilnawaz, A. Singh, C. Mohanty, and S.K. Sahoo Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy Biomaterials 31 2010 3694 3706
19. M.R. Dreher, W. Liu, C.R. Michelich, M.W. Dewhirst, F. Yuan, and A. Chilkoti Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers J. Natl. Cancer Inst. 98 2006 335 344 (Pubitemid 43338213)
20. J.L. Eiseman, N.D. Eddington, J. Leslie, C. MacAuley, D.L. Sentz, M. Zuhowski, J.M. Kujawa, D. Young, and M.J. Egorin Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice Cancer Chemother. Pharmacol. 34 1994 465 471 (Pubitemid 24306044)
21. M. Emi, R. Kim, K. Tanabe, Y. Uchida, and T. Toge Targeted therapy against Bcl-2-related proteins in breast cancer cells Breast Cancer Res. 7 2005 R940 R952
22. O.C. Farokhzad, and R. Langer Impact of nanotechnology on drug delivery ACS Nano 3 2009 16 20
23. M.L. Forrest, J.A. Yanez, C.M. Remsberg, Y. Ohgami, G.S. Kwon, and N.M. Davies Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity Pharm. Res. 25 2008 194 206
24. G. Gaucher, R.H. Marchessault, and J.C. Leroux Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes J. Controlled Release 143 2010 2 12
25. H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 37 2001 1590 1598 (Pubitemid 32778603)
26. J. Gligorov, and J.P. Lotz Preclinical pharmacology of the taxanes: implications of the differences Oncologist 9 2004 3 8 (Pubitemid 38747838)
27. B.R. Goldspiel Clinical overview of the taxanes Pharmacotherapy 17 1997 110S 125S (Pubitemid 27411251)
28. W.J. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. Hawkins, and J. O'Shaughnessy Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J. Clin. Oncol. 23 2005 7794 7803 (Pubitemid 46657376)
29. R.B. Greenwald, Y.H. Choe, J. McGuire, and C.D. Conover Effective drug delivery by PEGylated drug conjugates Adv. Drug Deliv. Rev. 55 2003 217 250 (Pubitemid 36135917)
30. P. Grodzinski, M. Silver, and L.K. Molnar Nanotechnology for cancer diagnostics: promises and challenges Expert Rev. Mol. Diagn. 6 2006 307 318 (Pubitemid 44174337)
31. J.P. Guastalla, C. Lhomme, J. Dauplat, M. Namer, J. Bonneterre, F. Oberling, P. Pouillart, P. Fumoleau, P. Kerbrat, and N. Tubiana Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: an interim analysis of a phase II multicenter study Ann. Oncol. 5 Suppl. 6 1994 S33 S38
32. R. Haag Supramolecular drug-delivery systems based on polymeric core-shell architectures Angew. Chem., Int. Ed. Engl. 43 2004 278 282 (Pubitemid 38090059)
33. I.C. Henderson, D.A. Berry, G.D. Demetri, C.T. Cirrincione, L.J. Goldstein, S. Martino, J.N. Ingle, M.R. Cooper, D.F. Hayes, K.H. Tkaczuk, G. Fleming, J.F. Holland, D.B. Duggan, J.T. Carpenter, E. Frei 3rd, R.L. Schilsky, W.C. Wood, H.B. Muss, and L. Norton Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J. Clin. Oncol. 21 2003 976 983 (Pubitemid 46594124)
34. M. Heney, M. Alipour, D. Vergidis, A. Omri, C. Mugabe, J. Th'ng, and Z. Suntres Effectiveness of liposomal paclitaxel against MCF-7 breast cancer cells Can. J. Physiol. Pharmacol. 88 2010 1172 1180
35. S.J. Holland, B.J. Tighe, and P.L. Gould Polymers for biodegradable medical devices. 1. The potential of polyesters as controlled macromolecular release systems J. Controlled Release 4 1986 155 180 (Pubitemid 17204842)
36. B. Johnson, B. Toland, R. Chokshi, V. Mochalin, S. Koutzaki, and B. Polyak Magnetically responsive paclitaxel-loaded biodegradable nanoparticles for treatment of vascular disease: preparation, characterization and in vitro evaluation of anti-proliferative potential Curr. Drug Deliv. 7 2010 263 273
37. R. Kunstfeld, G. Wickenhauser, U. Michaelis, M. Teifel, W. Umek, K. Naujoks, K. Wolff, and P. Petzelbauer Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model J. Invest. Dermatol. 120 2003 476 482 (Pubitemid 36298435)
38. K. Letchford, R. Liggins, K.M. Wasan, and H. Burt In vitro human plasma distribution of nanoparticulate paclitaxel is dependent on the physicochemical properties of poly(ethylene glycol)-block-poly(caprolactone) nanoparticles Eur. J. Pharm. Biopharm. 71 2009 196 206
39. Liang, Y., Qiao, Y., Guo, S., Wang, L., Zhai, Y., Xie, C., Hu, R., Deng, L., Dong, A., 2011. Investigation on injectable, thermally and physically gelable poly(ethylene glycol)/poly(octadecanedioic anhydride) amphiphilic triblock co-polymer nanoparticles. J. Biomater. Sci. Polym. Ed. January 28, Epub ahead of print.
40. R.T. Liggins, and H.M. Burt Polyether-polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations Adv. Drug Deliv. Rev. 54 2002 191 202 (Pubitemid 34230441)
41. J. Lim, and E.E. Simanek Synthesis of water-soluble dendrimers based on melamine bearing 16 paclitaxel groups Org. Lett. 10 2008 201 204
42. Z. Liu, K. Chen, C. Davis, S. Sherlock, Q. Cao, X. Chen, and H. Dai Drug delivery with carbon nanotubes for in vivo cancer treatment Cancer Res. 68 2008 6652 6660
43. J. Lu, M. Liong, S. Sherman, T. Xia, M. Kovochich, A.E. Nel, J.I. Zink, and F. Tamanoi Mesoporous silica nanoparticles for cancer therapy: energy-dependent cellular uptake and delivery of paclitaxel to cancer cells Nanobiotechnology 3 2007 89 95
44. H. Maeda The tumor blood vessel as an ideal target for macromolecular anticancer agents J. Controlled Release 19 1992 315 324
45. H. Maeda The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting Adv. Enzyme Regul. 41 2001 189 207
46. Milane, L., Duan, Z.F., Amiji, M., 2011. Biodistribution and pharmacokinetic analysis of combination lonidamine and paclitaxel delivery in an orthotopic animal model of multidrug-resistant breast cancer using EGFR-targeted polymeric nanoparticles. Nanomed. Nanotechnol. Biol. Med. January 8, Epub ahead of print.
47. T. Minko, M.L. Patil, M. Zhang, J.J. Khandare, M. Saad, P. Chandna, and O. Taratula LHRH-targeted nanoparticles for cancer therapeutics Methods Mol. Biol. 624 2010 281 294
48. A. Mitra, and S. Lin Effect of surfactant on fabrication and characterization of paclitaxel-loaded polybutylcyanoacrylate nanoparticulate delivery systems J. Pharm. Pharmacol. 55 2003 895 902 (Pubitemid 36916679)
49. C. Nardin, D. Bolikal, and J. Kohn Nontoxic block copolymer nanospheres: design and characterization Langmuir 20 2004 11721 11725 (Pubitemid 40049647)
50. T. Ohtsu, Y. Sasaki, T. Tamura, Y. Miyata, H. Nakanomyo, Y. Nishiwaki, and N. Saijo Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion Clin. Cancer Res. 1 1995 599 606
51. T. Ooya, J. Lee, and K. Park Hydrotropic dendrimers of generations 4 and 5: synthesis, characterization, and hydrotropic solubilization of paclitaxel Bioconjug. Chem. 15 2004 1221 1229 (Pubitemid 39552010)
52. A. Potineni, D.M. Lynn, R. Langer, and M.M. Amiji Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive biodegradable system for paclitaxel delivery J. Controlled Release 86 2003 223 234 (Pubitemid 36084272)
53. R. Reul, T. Renette, N. Bege, and T. Kissel Nanoparticles for paclitaxel delivery: a comparative study of different types of dendritic polyesters and their degradation behavior Int. J. Pharm. 407 2011 190 196
54. E. Rivera Liposomal anthracyclines in metastatic breast cancer: clinical update Oncologist 8 Suppl. 2 2003 3 9 (Pubitemid 37152051)
55. L. Sheihet, P. Chandra, P. Batheja, D. Devore, J. Kohn, and B. Michniak Tyrosine-derived nanospheres for enhanced topical skin penetration Int. J. Pharm. 350 2008 312 319
56. L. Sheihet, R.A. Dubin, D. Devore, and J. Kohn Hydrophobic drug delivery by self-assembling triblock copolymer-derived nanospheres Biomacromolecules 6 2005 2726 2731 (Pubitemid 41388286)
57. L. Sheihet, K. Piotrowska, R.A. Dubin, J. Kohn, and D. Devore Effect of tyrosine-derived triblock copolymer compositions on nanosphere self-assembly and drug delivery Biomacromolecules 8 2007 998 1003 (Pubitemid 46488484)
58. D. Shenoy, S. Little, R. Langer, and M. Amiji Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs. Part 2: In vivo distribution and tumor localization studies Pharm. Res. 22 2005 2107 2114 (Pubitemid 41821590)
59. S. Song, B. Yu, Y. Wei, M.G. Wientjes, and J.L. Au Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors Clin. Cancer Res. 10 2004 6058 6065 (Pubitemid 39287510)
60. A. Sparreboom, C.D. Scripture, V. Trieu, P.J. Williams, T. De, A. Yang, B. Beals, W.D. Figg, M. Hawkins, and N. Desai Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol) Clin. Cancer Res. 11 2005 4136 4143 (Pubitemid 40791578)
61. A. Sparreboom, L. van Zuylen, E. Brouwer, W.J. Loos, P. de Bruijn, H. Gelderblom, M. Pillay, K. Nooter, G. Stoter, and J. Verweij Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications Cancer Res. 59 1999 1454 1457 (Pubitemid 29160110)
62. S. Stolnik, S.E. Dunn, M.C. Garnett, M.C. Davies, A.G. Coombes, D.C. Taylor, M.P. Irving, S.C. Purkiss, T.F. Tadros, and S.S. Davis Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers Pharm. Res. 11 1994 1800 1808 (Pubitemid 24377094)
63. M. Sui, Y. Huang, B.H. Park, N.E. Davidson, and W. Fan Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death Cancer Res. 67 2007 5337 5344 (Pubitemid 46997273)
64. Y. Tabuchi, J. Matsuoka, M. Gunduz, T. Imada, R. Ono, M. Ito, T. Motoki, T. Yamatsuji, Y. Shirakawa, M. Takaoka, M. Haisa, N. Tanaka, J. Kurebayashi, V.C. Jordan, and Y. Naomoto Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer Int. J. Oncol. 34 2009 313 319
65. A.J. ten Tije, J. Verweij, W.J. Loos, and A. Sparreboom Pharmacological effects of formulation vehicles: implications for cancer chemotherapy Clin. Pharmacokinet. 42 2003 665 685 (Pubitemid 36936530)
66. D.L. Toppmeyer, M. Gounder, J. Much, R. Musanti, V. Vyas, M. Medina, T. Orlando, M. Pennick, Y. Lin, W. Shih, S. Goodin, and E. Rubin A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy Med. Sci. Monit. 9 2003 PI99 PI104
67. V.P. Torchilin Structure and design of polymeric surfactant-based drug delivery systems J. Controlled Release 73 2001 137 172 (Pubitemid 32544594)
68. Tsallas, A., Jackson, J., Burt, H., 2010. The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations. Cancer Chemother. Pharmacol. November 11. Epub ahead of print.
69. V. Vassileva, J. Grant, R. De Souza, C. Allen, and M. Piquette-Miller Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model Cancer Chemother. Pharmacol. 60 2007 907 914 (Pubitemid 47389398)
70. Y.C. Wang, L.Y. Tang, T.M. Sun, C.H. Li, M.H. Xiong, and J. Wang Self-assembled micelles of biodegradable triblock copolymers based on poly(ethyl ethylene phosphate) and poly(-caprolactone) as drug carriers Biomacromolecules 9 2008 388 395 (Pubitemid 351201624)
71. R.B. Weiss, R.C. Donehower, P.H. Wiernik, T. Ohnuma, R.J. Gralla, D.L. Trump, J.R. Baker Jr., D.A. Van Echo, D.D. Von Hoff, and B. Leyland-Jones Hypersensitivity reactions from taxol J. Clin. Oncol. 8 1990 1263 1268 (Pubitemid 20195638)
72. Z.K. Xu, F.Q. Nie, C. Qu, L.S. Wan, J. Wu, and K. Yao Tethering poly(ethylene glycol)s to improve the surface biocompatibility of poly(acrylonitrile-co-maleic acid) asymmetric membranes Biomaterials 26 2005 589 598 (Pubitemid 38988301)
73. A.S. Zahr, and M.V. Pishko Encapsulation of paclitaxel in macromolecular nanoshells Biomacromolecules 8 2007 2004 2010 (Pubitemid 47009983)
74. M. Zhao, C. Liang, A. Li, J. Chang, H. Wang, R. Yan, J. Zhang, and J. Tai Magnetic paclitaxel nanoparticles inhibit glioma growth and improve the survival of rats bearing glioma xenografts Anticancer Res. 30 2010 2217 2223